May 19, 2003 -- IMPAX Laboratories, Inc. (Nasdaq:IPXL) today announced that,
at its Annual Meeting held May 15, 2003, shareholders voted to re-elect all
members of its Board of Directors. The following individuals were re-elected
to serve until the next Annual Meeting of Shareholders: Messrs. Robert L. Burr,
Barry R. Edwards, David J. Edwards, Michael Markbreiter, Oh Kim Sun, Peter R.
Terreri and Drs. Leslie Z. Benet, Nigel Fleming, Charles Hsiao and Larry Hsu.
The IMPAX shareholders also ratified the appointment of PricewaterhouseCoopers
LLP as the Company's independent certified public accountants for the 2003 fiscal
year.
IMPAX has 19 applications pending at the FDA, including three tentatively approved,
that address approximately $6.0 billion in U.S. branded product sales for the
twelve months ended December 31, 2002. Fourteen of these filings were made under
Paragraph IV of the Hatch-Waxman Amendments.
IMPAX Laboratories, Inc. is a technology-based specialty pharmaceutical company
applying its formulation expertise and drug delivery technology to the development
of controlled-release and specialty generics, in addition to the development
of branded products. IMPAX markets its generic products through its Global Pharmaceuticals
division and intends to market its branded products through the IMPAX Pharmaceuticals
division. Additionally, where strategically appropriate, IMPAX has developed
marketing partnerships to fully leverage its technology platform. IMPAX Laboratories
is headquartered in Hayward, California, and has a full range of capabilities
in its Hayward and Philadelphia facilities. For more information, please visit
the Company's Web site at: www.impaxlabs.com.